Semaglutide Linked to Reduced Migraine Medication Use in Women
Semaglutide use was associated with reduced migraine medication (triptan) consumption in women, but not men, according to a Danish registry study.
Atlas Newsdesk ·
A recent study indicates that women initiating semaglutide treatment experienced a reduction in triptan use, a common migraine medication. This effect was not observed in men.
The study, based on Danish health registry data, tracked triptan consumption for two years prior to and one year following semaglutide initiation. Approximately 4.6% of individuals used triptans during the study period.
Women showed an 8% reduction in triptan use
Women showed an 8% reduction in triptan use after starting semaglutide, with the most significant decreases in younger adults (18-35). Individuals with a history of preventive migraine medication use also experienced a more pronounced reduction.
No significant change was noted in the number of new triptan users, suggesting semaglutide may mitigate existing migraine symptoms rather than prevent new occurrences. The observed changes in triptan use were gradual over time.